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Abstract The aim of the study is to compare the efficacy
of SPIO as a tracer in sentinel node biopsy (SNB) in breast
cancer with Tc and patent blue in a multicentre prospective
study and perform a meta-analysis of all published studies.
It also aims to follow skin discoloration after SPIO injec-
tion and describe when and how it resolves. Totally 206
patients with early breast cancer were recruited. Tc and
patent blue were administered in standard fashion. Patients
were injected with SPIO (Sienna?) preoperatively. SNB
was performed and detection rates were recorded for both
methods. Skin discoloration was followed and documented
postoperatively. Data extraction and subsequent meta-
analysis of all previous studies were also performed. SN
detection rates were similar between standard technique
succeeded and SPIO both per patient (97.1 vs. 97.6 %,
p = 0.76) as well as per node (91.3 vs. 93.3 %, p = 0.34),
something which was not affected by the presence of
malignancy. Concordance rates were also consistently high
(98.0 % per patient and 95.9 % per node). Discoloring was
present in 35.5 % of patients postoperatively, almost
exclusively in breast conservation. It fades slowly and is
still detectable in 8.6 % of patients after 15 months. Meta-
analysis depicted similar detection rates (p = 0.71) and
concordance rates (p = 0.82) per patient. However, it
seems that SPIO is characterized by higher nodal retrieval
(p\ 0.001). SPIO is an effective method for the detection
of SN in patients with breast cancer. It is comparable to the
standard technique and seems to simplify logistics.
Potential skin discoloration is something of consideration
in patients planned for breast conservation.
Keywords Sentinel node  Super paramagnetic iron oxide 
Breast cancer
Introduction
Sentinel node biopsy (SNB) currently constitutes the
standard of care for staging of the clinically and radio-
logically negative axilla in breast cancer surgery [1, 2].
Nowadays, it is accepted as the sole surgical procedure in
the axilla when the sentinel node (SN) is proven negative
or, in some cases even in the presence of metastases [3].
Additionally, neoadjuvant treatment for breast cancer has
further widened the indications of SNB [4].
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Identification of the SN is based on the use of a
radioactive tracer, most often in combination with a vital
dye injected interstitially, either close to the areola or
around the tumor. The combination of these two methods
has been established as the gold standard for the detection
of the SN. Their simultaneous use has been clearly shown
to increase the detection rate in figures up to 96–97 %, as
depicted in the ALMANAC and AMAROS trials [1, 5].
There are, however, some drawbacks. The use of an iso-
tope demands a nuclearmedicine department. The short half-
life (6 h) of Technetium 99 m (Tc) limits its usefulness and
also confers possible hazards to the patient and staff.
Moreover, complicated legislation and restrictions regulate
the handling and disposal of radioactive material. All these
limit the access to the method. Interestingly, recent literature
reports that only 60 % of patients in developed countries
have access to the procedure, with this figure dropping down
to 5 % in China and even lower in the rest of the world [6].
The vital dye is allergenic, and has been associated with a
few serious events [7, 8]. These facts stress the need for non-
radioactive and non-allergenic tracers with an ability to
detect the SN comparable to the traditional methods.
Superparamagnetic iron oxide nanoparticles (SPIO)
have been used in the past as contrast agents for magnetic
resonance imaging (MRI). Sienna? is a brown solution
containing dextran-coated SPIO particles with a particle
size of 59 nm. After injection in the breast, Sienna? drains
through the lymphatics and accumulates in the SN. A
handheld probe, SentiMag, is used to identify the SN, in the
same way as the gamma probe is used for detection of
isotope-containing nodes. The solution is dark brown, and
the nodes are often colored, which can help the surgeon
identify the SN visually as well. The nodes marked as
sentinels can be visualized with MRI [9]. The method has
been compared to the standard technique with results ver-
ifying non-inferiority [10–16]. However, the tracer has
been noted to have a tendency to discolor the skin at the
injection site in the breast, similar to what is found after
injection of blue dye [12–16].
The aims of the present study were to compare detection
rate with SPIO versus conventional technique, to describe
the frequency and duration of discoloration, and to perform
a meta-analysis of published data on detection and con-
cordance between the different techniques.
Materials and methods
Study design
The Nordic SentiMag study is an international prospective
multicenter trial, recruiting patients in 5 Swedish and 2
Danish hospitals with experience in SNB. All participating
surgeons were trained in the methodology of the study and
the function of the device and the surgical technique was
thereafter standardized.
Patient selection
Patients were eligible for recruitment if they were older
than 18 years, diagnosed with breast cancer or ductal car-
cinoma in situ, with clinically and ultrasonographically
negative axilla, and scheduled for SNB. Exclusion criteria
were hypersensitivity to dextran compounds, iron or
Sienna? , isotope intolerance, iron overload disease,
pregnancy, pacemaker or other implantable metallic devi-
ces close to the axilla, or mental condition rendering the
patient incapable of giving informed consent. All patients
had to be available for postoperative follow-up. Appro-
priate candidates were identified from case presentations in
the multidisciplinary rounds. All patients received oral and
written information and signed informed consent. The
ethics committee in Uppsala University in Sweden and
Videnskabsetiske Komite´, Region Midt in Denmark
approved the study.
Fig. 1 PRISMA flow chart for the conduct of the meta-analysis
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Operative protocol
Patients were injected with the radioactive tracer (99mTc),
usually 40–60 mBq, either on the day of surgery or the day
before. Injection could be made subareolarly, subdermally,
or subcutaneously above the tumor according to local
standards. Lymphoscintigraphy was not performed rou-
tinely. A vital blue dye (1–2 ml of Patent Blue V) was
injected in standard fashion after the onset of anesthesia.
Two ml of Sienna? diluted with 3 ml saline was injected
subareolarly either shortly before or after induction of
anesthesia. The injection site was massaged for 5 min, and
the operation was not to start until at least 20 min had
elapsed.
During operation, a handheld probe (SentiMag,
Endomagnetics Ltd, UK) was first used to detect magnetic
uptake. A short incision was made in the axilla over the
area with the greatest uptake, and the sentinel node was
sought for primarily using the SentiMag probe. Metal
retractors and instruments were removed and plastic ones
were used at that point. Thereafter the finding was con-
firmed with the gamma probe and the SN(s) removed. All
SNs were excised until the counts were lower than 10 % of
the highest count or a maximum of four nodes per patient
were removed. Blue and/or brown nodes were also
regarded as SNs. Magnetic and gamma counts were reg-
istered before the skin incision; in situ and ex vivo in the
SNs; and in the remaining axilla.
Patients were followed postoperatively and any discol-
oration was registered and measured repeatedly.
Pathology
All nodes were examined with hematoxylin–eosin staining.
Frozen section was performed according to hospital policy.
Immunohistochemistry was used in cases where no
metastases were found with hematoxylin–eosin. Additional
techniques were used according to the pathologist’s
discretion.
Statistical methods: study endpoints
The study assumes a 97 % proportion detected by con-
ventional SNB and SPIO SNB, a limit difference for
equivalence of -4 % and the expected difference between
the proportions detected under both arms as 0 %. This
means that equivalence is accepted if the proportion
detected under the SPIO arm is as low as 93 %. Detection
rate was additionally tested in a right-sided binominal test
with the alternative hypothesis that the proportion of















A clearly stated aim 2 2 2 2 2 2 2
Inclusion of consecutive patientsa 1 1 2 2 2 1 2
Prospective collection of data 2 2 2 2 2 2 2
Endpoints appropriate to the aim
of the study
2 2 2 2 2 2 2
Unbiased assessment of the study
endpointb
2 2 2 2 2 2 2
Follow-up period appropriate to
the aim
2 2 2 2 2 2 2
Loss to follow up less than 5 %c 2 2 2 2 2 2 2
Prospective calculation of the
study size
2 1 2 1 2 2 2
An adequate control group 2 2 2 2 2 2 2
Contemporary groups 2 2 2 2 2 2 2
Baseline equivalence of groups 2 2 2 2 2 2 2
Adequate statistical analyses 2 2 2 2 2 2 2
Total 23 22 24 23 24 23 24
Not reported:0, Reported but inadequate:1, Reported and adequate:2
a No exclusion or details about the reasons for exclusion
b If not blind, it has to be explained
c If important for primary endpoint
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successful SNBs was greater than 93 % for each tracer.
Prospective sample size for a paired test with a 0.05 one-
sided significance level and 80 % power to reject the null
hypothesis was 214 cases.
The primary endpoint of the study was the proportion of
successful SNBs (detection rate per case) with either the
standard (radioisotope ± blue dye) or the magnetic tech-
nique (SPIO). Secondary endpoints included the proportion
of SN detected (nodal detection rate) as well as the pro-
portion of pathologically positive results (malignancy rate)
per case and per node with either technique. Moreover, the
concordance and reverse concordance for successful
detections (per patient and per node, overall and in terms of
malignancy) are compared. Concordance is defined as the
number of both standard (radioisotope and blue dye or
radioisotope alone) and SPIO-positive patients or nodes,
divided by the number of patients or nodes marked by the
standard method (standard? and SPIO?/standard?).
Reverse concordance is defined as the number of both
standard- and SPIO- positive patients or nodes, divided by
the number of patients or nodes marked by the SPIO tracer
(standard? and SPIO?/SPIO?). Only tumor positive
patients and nodes are included in the respective malig-
nancy concordance rates. Additionally, the false negatives
of the method and the overlap between the conventional
and the magnetic technique were addressed. Finally, skin
discoloration and concomitant transcutaneous magnetic
activity were followed and registered.
For all data, a 95 % Bayes confidence interval (95 %CI)
was calculated on the basis of binominal distribution.
Means (95 % Confidence Intervals, 95 %CI) or medians
(interquartile range, IQR) are presented as appropriate after
Kolmogorov–Smirnov and Shapiro–Wilk tests of normality
are performed. Rates are presented with 95 % CI. A
p value of\0.05 will indicate that the null hypothesis was
rejected. Values were calculated using SPSS (V 22.0.
Armonk, NY: IBM Corp.).
While the Nordic study was undertaken, several other
comparative studies were published. A meta-analysis was
undertaken to extract definitive results. Study selection and
data extraction was performed independently by two
authors (Fig. 1). Endpoints from the data extraction and
calculation included detection rates per case and per node,
including malignancy, where available. Heterogeneity
among studies was assessed (I2). Dichotomous data were
analyzed estimating the pooled odds ratio (OR), according
the Mantel–Haenszel method. Concordance rates were also
recalculated and presented. Rate comparison was per-
formed using the inverse variance method. All studies
included in the meta-analysis were evaluated according the
revised MINORS criteria [17] by an author which was not
involved in the Nordic study (Table 1). Analysis was
conducted using the RevMan 5.3 software.
Results
A total of 206 patients and procedures were included in the
study. Mean age was 61.7 years (60.1, 63.4) and median
BMI 25.4 (7.1). Mean tumor size was 19.0 mm (16.9, 21.2)
with values ranging from 1 to 150 mm. [Blue was used in
127 patients (61.7 %)]. Patient and tumor characteristics
are shown in Table 2.
The transcutaneous detection with Tc was successful in
202 of 206 patients (98.1 %; 94.8, 99.4), and with Sien-
na? only in 189 (91.7 %; 86.9, 95.0), resulting in a 6.4 %
difference (p = 0.0036). Correlation analysis showed that
the value of the transcutaneous signal in both methods was
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associated with BMI both for Tc (Spearman’s q: -0.167,
p\ 0.05) and for Sienna? (Spearman’s q: -0.191,
p\ 0.01). Age, tumor size, time between injection and
operation and previous surgery did not correlate with
transcutaneous detection.
SN detection with the standard technique succeeded in
200 patients (97.1 %; 93.5, 98.8) and 201 with
Sienna? (97.6 %; 94.1, 99.1), displaying no difference
(p = 0.76). Both techniques were successful concomi-
tantly in 196 cases (95.1 %; 91.0, 97.5). Subsequently, per
patient concordance was 98.0 % (94.6, 99.3) and reverse
concordance was 97.5 % (94, 99.1). Total failure for both
techniques occurred in only one patient (0.48 %), who had
multiple macrometastases. Metastases were noted in 54
patients (26.2 %; 20.5, 32.9). These were detected by both
methods in 52 cases (96.3 %; 86.2, 99.4), Tc in 53
(98.1 %; 88.8, 99.9) and Sienna? in 52 (96.3 %; 86.2,
99.4) resulting in concordance and reverse concordance
per malignant case of 98.1 % (88.8, 99.9) and 100 %
(91.3, 100), respectively. Per patient data of the Nordic
study and studies included in the meta-analysis are pre-
sented in Tables 3 and 4.
A total of 403 SNs were retrieved. Out of these, 353
were detected by both techniques, [87.6 % (83.9, 90.6)];
368 with the standard technique, [mean 1.79 (1.65, 1.92)
and detection rate 91.3 % (88.0, 93.8)]; 376 with
Sienna? , [mean 1.83 (1.69, 1.96) and detection rate
93.3 % (90.3, 95.5)], (p = 0.34). The nodal concordance
and reverse concordance were 95.9 % (93.2, 97.6) and
93.9 % (90.8, 96.0), respectively. Out of the total 403
nodes, 68 (16.9 %; 13.4, 21.0) were malignant. Tc detec-
ted 63 (92.6 %; 83.0, 97.3) and Sienna? 62 (91.2 %; 81.1,
96.4), whereas both succeeded simultaneously in 60 nodes
(88.2 %; 77.6, 94.4). The concordance and reverse con-
cordance for malignant nodes were 95.2 % (85.6, 98.8)
and 96.8 % (87.7, 99.4). Per node data of the Nordic study
and studies included in the meta-analysis are presented in
Tables 5 and 6.
In cases where SNB failed, no risk factors were iden-
tified regardless of technique, neither in our material nor in
the rest of the studies included in the meta-analysis.
Discoloration
Follow-up data were available in 186 of 206 patients
(90.3 %). The initial protocol stated a follow-up visit after
6 months, but since a marked discoloration was found in a
considerable amount of women, the follow-up period was
extended. Thus, median follow-up was 310 days (IQR
182). Correlation analysis showed that the incidence of
discoloring was strongly associated with breast conserving
surgery (Kendall tau = -0.416, p\ 0.001), since 95.6 %
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conserving surgery (BCS). Age, BMI, or the incidence of
perioperative staining did not correlate (p[ 0.5).
Discoloration was present in 35.5 % of patients post-
operatively (0–3 months) and faded progressively in size
and color over time to 21 % of patients after a year.
Staining remained present in 8.6 % 15 months after the
operation, but much smaller and paler. Discoloration for
the entire cohort and the BCS group are essentially the
same (within 95 %CI). Additionally, the curve demon-
strated below in Fig. 2 is identical for both.
Finally, all the patients who had discoloration and were
checked with the probe transcutaneously presented mag-
netic activity (positive prognostic value 100 %); however,
no correlation of the transcutaneous counts was found
with size, intensity, or duration of the skin discoloration.
Meta-analysis
Seven studies were included (ref. 10-15 and our study) with
a total of 1118 cases performed and 2300 nodes retrieved.
No difference was observed in the detection rates per case
in any of the studies (fixed OR 1.10; 0.67, 1.79, p = 0.71)
between SPIO and conventional methods (Fig. 3).
However, moderate heterogeneity was present
(I2 = 48 %) among the studies as far as nodal detection
rate was concerned. Three studies (10,12,15) demonstrated
higher detection rate per node with SPIO (Table 5). Sub-
sequently, the random OR was 1.84 (1.37,2.47), resulting
in significant difference in favor of SPIO (p\ 0.0001)
compared to the conventional method, as seen in Fig. 4.
As to malignancy rates per case and per node, two
studies [10, 12] did not present complete relevant data. The
detection rates in cases with a positive SNB were compa-
rable for both methods (fixed OR:1.33; 0.63, 2.81,
p = 0.45) (Fig. 5), as well as detection rates per malignant
nodes (fixed OR:1.55; 0.86, 2.79, p = 0.14) (Fig. 6).
Concordance and reverse concordance rates were
recalculated for all included studies according to the defi-
nitions (standard? and Sienna ?/standard?) and (stan-
dard? and SPIO ?/SPIO?) with 95 %CI. No substantial
differences were noted (Table 7).
Subsequent inverse variance analysis was conducted
using ‘‘risk difference’’ defined as |Concordance-Reverse
concordance|, depicting similar rates per case among
studies (p = 0.82) (Fig. 6). The comparison of concor-
dance rates per node however revealed heterogeneity
among the studies (I2 = 54 %), as well as that more SNs
are detected with SPIO (p = 0.0003) (Fig. 7). The same
comparisons were conducted in the presence of malig-
nancy, without any evidence that imply a difference per
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Fig. 2 Discoloration in the
follow-up cohort; size and the
colour of the spheres represent
the medians of the discoloured
surface in cm2 in the
discoloured proportion of the
cohort and the fading,
respectively
Fig. 3 Forest plot comparing detection rates per patient
Fig. 4 Forest plot comparing detection rates per node
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Discussion
This multicenter study, as well as the meta-analysis per-
formed, confirms that SPIO can be used as a safe alterna-
tive to the conventional technique. The use of Tc ± blue
dye has been the standard of care in almost 20 years and
statistical superiority of any new method is hard to
demonstrate mostly in terms of discrepancy in numbers of
patients. However, the motivation for the development of
new techniques has risen from the drawbacks of the con-
ventional methods. The use of SPIO has been reported
before [18]. The current study verifies that detection rates
do not differ and the presence of metastases does not affect
the effectivity of the method. Constantly high concordance
rates between methods also suggest that SPIO identify the
‘‘right’’ SN. One more conclusion from the meta-analysis is
the higher nodal rate for SPIO, possibly resulting in the
retrieval of more SNs, a finding not confirmed in our study.
However, the clinical significance and utility of that remain
to be defined.
The current study confirms findings from other groups
[13–15] that it can be easier to use without the restrictions
in the availability, use, manipulation, and disposal of the
isotope [19, 20].
The brownish coloring of the SN when SPIO is used
has been commented [10, 12–16] as an aid intraopera-
tively. We made the same observation, but it was diffi-
cult to quantify due to the presence of ink. The utility of
an optic tracer is of value, as shown for the blue dye
[21]. However, it is a complementary property in the
presence of isotope localization [22]. Still, it seems that
SPIO may offer the same, with none of the blue dye
disadvantages [23–27].
Advantages of the study include the adherence to a
distinct protocol and feedback that the technique is easily
adopted among surgeons experienced with the SN tech-
nique, a conclusion reached by other groups [15, 28]. A
weakness of the study is that the simultaneous use of both
methods made it difficult to disentangle detection by either
method and to define overlapping between the two.
Another observation of our group in agreement with
Thill et al. [11] was that lower transcutaneous signals were
found in patients with higher BMI which is shown in our
results, but, despite the difference between transcutaneous
and overall detection rates for SPIO (p\ 0.05), it is of no
consequence after the skin incision is made. This means
that a low transcutaneous signal should not discourage the
surgeon.
Fig. 5 Forest plot comparing detection rates per patient in the presence of malignancy
Fig. 6 Forest plot comparing detection rates per node in the presence of malignancy
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Table 7 Concordance and reverse concordance rates per study are presented as linears with 95 %CI
Study (Ref.) Concordance (95 % CI) Reverse concordance (95 % CI)
Douek et al. [10] 96.0 (91.2, 98,4) 96.7 (92, 98.8)
Thill et al. [11] 99.3 (95.7, 99.9) 98.6 (94.7, 99.8)
Rubio et al. [12] 98.2 (93.1, 99.7) 95.7 (89.7, 98.4)
Pineiro et al. [13] 99.4 (96.4, 99.9) 100 (97.4,100)
Ghilli et al. [14] 95.9 (91.8, 98.1) 96.9 (93, 98.7)
Hopeau et al. [15] 99.0 (93.9, 100) 97.1 (91.8, 99.4)
Nordic study 98.0 (94.6, 99.4) 97.5 (94, 99)
90 91 92 93 94 95 96 97 98 99 100
Concordance rates with 95%CI
Douek et al,2014
Thill et al, 2014
Rubio et al, 2015
Pineiro et al, 2015
Ghilli et al, 2015
Houpeau et al, 2016
Nordic
88 90 92 94 96 98 100
Reverse Concordance rates with 95%CI
Douek et al,2014
Thill et al, 2014
Rubio et al, 2015
Pineiro et al, 2015
Ghilli et al, 2015
Fig. 7 Forest plot comparing concordance versus reverse concordance per patient
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If SPIO would have been the only option, some nodes
might have been more difficult to find, since the probe is a
little bigger than the gamma probe, and the operating field
was sometimes covered by the probe. This was a common
finding in all studies. That remark has been addressed by a
slimmer version of the probe. The distortion of the ferro-
magnetic signal by metallic instruments has also been
addressed by the removal of metallic instruments when the
probe is to be used, or by the use of plastic instruments
[15].
Discoloration in the form of a brown-grayish tattoo has
been briefly mentioned previously [12–16]. Rubio et al.
[12], reported discoloration in 19 %, which faded pro-
gressively after 6 months, comparable to the effect pro-
duced by blue dye. Pin˜ero et al. [13] report the
pigmentation, whereas Ghilli et al. [14] report an incidence
of 40 % at 6 months which is transient in 91 % of pig-
mented cases. Similar observations regarding staining were
made with the use of another type of SPIO, ferucarbotran,
in which a skin stain that lasted 2 months and resolved
spontaneously thereafter was described [18]. Recent
experimental data comparing three different types of SPIO
on a porcine model noted skin discoloration as a common
fact, but no follow-up was performed [29]. The absence of
Fig. 8 Forest plot comparing concordance versus reverse concordance per node
Fig. 9 Forest plot comparing concordance versus reverse concordance per patient in the presence of malignancy
Fig. 10 Forest plot comparing concordance versus reverse concordance per node in the presence of malignancy
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data motivated follow-up and quantification of this effect.
Postoperatively, it was present in 35.5 % of patients and
faded slowly over time. In 8.6 %, a pale discoloration was
present after 15 months. In most cases, it would shrink and
fade; in some others it faded by spreading, like a subcu-
taneous hematoma. Therefore, it is something that should
be kept in mind when informing a patient.
The discoloration found after Sienna ? injections
implies that the substance remains for a long time in the
breast. In a small pilot study [30], our group showed that it
remains for at least up to 3 weeks in the SN, and can easily
be measured after that time with higher counts transcuta-
neously as well as in situ and ex vivo. In our trial, this was
confirmed since magnetic counts were present in the tissue
up to 515 days after the operation. Therefore, injection of
Sienna? could be administered prior to the operation, thus
facilitating planning and logistics. Moreover, it implies that
a deeper peritumoral injection with subsequent excision of
that area, such as that proposed by Ghilli et al. [14], may
result in smaller or no discoloration.
Other methods such as the use of near-infrared (NIR)
imaging with indocyanine green (ICG) have presented
interest. However, disadvantages in the method include the
complexity of the procedure and the longer learning curve;
the high complexity and cost of the infrared camera; the
higher mean (3.41) of nodes retrieved, possibly implying
bigger morbidity; the skin pigmentation over a period of
time; and the impaired detection in cases of high body mass
index [31, 32].
One theoretical disadvantage of SPIOs is the inability to
obtain a simple and cheap preoperative localization scan,
which is of importance for localization of SN in melanoma
patients. However, it is not necessary to perform a preop-
erative scintigraphy for the detection of SN in patients with
breast cancer (5), and most centers have abandoned it.
Besides, SPIOs can identify SN in axillary MRI in patients
with breast cancer [9] and SPIO injection as a contrast
material in MR sentinel lymphography and as a tracer in
SN biopsy using an integrated method [33, 34], with
excellent imaging quality, in contrast to the poor spatial
resolution of scintigraphy. This may be a promising per-
spective in cases where preoperative localization will still
be needed such as in melanomas of the trunk and head and
neck, and recurrent breast cancer, where the lymphatic
drainage is sometimes distorted.
Upon the completion of this trial, a group from USA
analyzed the data from the first five trials [35]. In the
current trial, we present two more studies with additional
features and comprehensively investigate skin discol-
oration. The fact that similar statistical conclusions are
reached despite minor differences in methodology
strengthens the quality of clinical information on this
topic.
In conclusion, current research has shown non-inferiority
for SPIO over conventional techniques for SN detection.
This new method has none of the disadvantages of the
standard technique and is promising as a safe and effective
alternative in the absence of nuclear medicine facilities.
The SentiMag detection system and Sienna ? vials
were provided by Sysmex Europe during the study.
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